What are the nursing concerns associated with interferon‑beta therapy for multiple sclerosis?

Nursing Concerns for Interferon-Beta Therapy in Multiple Sclerosis

Nurses managing MS patients on interferon-beta must prioritize monitoring for injection site reactions (occurring in 84% of patients), flu-like symptoms (68% of patients), hepatotoxicity, depression/suicidal ideation, and ensuring proper injection technique with site rotation to prevent skin necrosis. 1, 2

Critical Safety Monitoring Requirements

Immediate Assessment Priorities

Injection Site Reactions (ISR)

• Occur in 84% of patients, typically within 5 days of injection and lasting 2-14 days 2
• Most common manifestation is erythema (39% of patients) 2
• Assess every injection site for necrosis - this requires immediate intervention and potential therapy discontinuation 1
• Do not allow patients to inject into affected areas until fully healed; if multiple lesions develop, discontinue therapy 1
• Teach and periodically re-evaluate proper aseptic injection technique 1

Flu-Like Symptoms (FLS)

• Affect 68% of patients, occurring predominantly within 6 hours post-injection and lasting <12 hours 2
• Most frequent symptoms: fatigue (15%) and aching limbs (15%) 2
• Prophylactic analgesics/antipyretics on injection days significantly reduce symptom burden 1, 3
• Symptoms typically decrease over time - only 10% report FLS at study endpoints 1

Laboratory Monitoring Schedule

Mandatory blood work intervals 1:

• Baseline: Complete blood count with differential, platelet count, comprehensive metabolic panel including liver function tests
• Months 1,3, and 6: Repeat all baseline labs
• Thereafter: Periodic monitoring in absence of clinical symptoms

Specific laboratory concerns:

• Leukopenia: Reported in 18% of patients (vs 6% placebo) - may require dose reduction 1
• Hepatotoxicity: Monitor transaminases; consider discontinuation if serious hepatic injury occurs 1
• Thrombocytopenia: Part of potential thrombotic microangiopathy syndrome 1

Life-Threatening Complications Requiring Immediate Action

Depression and Suicidal Ideation 1

• Instruct patients to immediately report any depressive symptoms or suicidal thoughts
• Consider therapy discontinuation if depression develops
• This is a boxed warning-level concern

Anaphylaxis 1

• Discontinue immediately if anaphylaxis occurs
• Ensure patients understand emergency response procedures

Thrombotic Microangiopathy (TMA) 1

• Monitor for thrombocytopenia, hemolytic anemia, renal dysfunction
• Can occur weeks to years after treatment initiation
• Discontinue therapy immediately if TMA suspected

Pulmonary Arterial Hypertension (PAH) 1

• Assess for unexplained dyspnea, new/increasing fatigue
• Can develop years after treatment initiation
• Discontinue if PAH confirmed after ruling out alternative etiologies

Congestive Heart Failure 1

• Monitor patients with pre-existing CHF for symptom worsening
• Consider discontinuation if CHF exacerbates

Patient Education and Adherence Support

Injection Technique Training

Critical teaching points 2, 4:

• Site rotation is essential - used by 58% of adherent patients as primary preventive measure 2
• Proper subcutaneous injection depth and angle
• Aseptic technique to prevent infection and necrosis 1
• Consider autoinjector devices to improve consistency 4

Titration Protocol

Start low and go slow 3, 5:

• Begin at 0.0625 mg (0.25 mL) every other day
• Increase over 6-week period to full dose of 0.25 mg (1 mL) every other day 1
• Titration significantly improves tolerability and reduces discontinuation 3, 4

Symptom Management Strategies

For ISR 2:

• Topical ointments for local reactions
• Systemic treatments if needed
• Alternating injection sites (most effective preventive measure)
• Cold compresses before/after injection

For FLS 3, 4:

• Prophylactic NSAIDs or acetaminophen taken 30 minutes before injection and continued for 24 hours
• Evening injections allow patients to sleep through symptoms
• Adequate hydration

Adherence Optimization

Nurse support is critical - the START study demonstrated 78.1% adherence at 12 months with structured nursing support including 3:

• Live training session at initiation
• Two telephone calls during first month
• Monthly follow-up calls thereafter
• Frequent assessment of injection technique

First year is highest risk period for discontinuation 4. Intensive nursing support during this period is essential for long-term treatment success.

Special Populations

Pregnancy planning 6:

• IFN-β-1a remains an important option around pregnancy and lactation
• Discuss with patients of childbearing potential

Aging patients 6:

• May be preferred over long-term immunosuppressive therapies
• MS activity naturally declines with age

Common Pitfalls to Avoid

• Failing to rotate injection sites - leads to lipodystrophy and increased ISR risk
• Not providing prophylactic analgesics - single most effective intervention for FLS
• Inadequate initial training - poor technique increases complications
• Missing early signs of depression - can be subtle and progressive
• Delaying laboratory monitoring - hepatotoxicity and cytopenias require early detection